1Delevaux I, Andre M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes. Ann Rheum Dis ,2003,62 (4) :337 - 340.
2Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr,2006,118 (5-6) :170 - 174.
3Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procaleitonin and C-reactive protein measurements for estiroation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis, 2008,61 ( 2 ) : 170 - 174.
4Christ-Crain M,Stolz D, Bingisser R,et al. Procalcitonin guidance of antibiotic therapy in Communtity-acquired pneumonia:a tandomized trial. Am J Respir Crit Care Med ,2006,174 (1) :84 -93.
5Menendez R, Cavaleanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax,2008, 63(5) :447 -452.
7Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD : a randomized , controlled trial comparing procalcitonin-guidance with standard therapy. Chest,2007,131 ( 1 ) : 9-19.
9Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community - acquired pneumonia. Intensive Care Med,2006,32(3) :469 -472.
10Oppert M, Reinicke A, Muller C, et al. Elevations in procaleitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation ,2002,53 (2) : 167 - 170.
二级参考文献18
1Reinhart K, Carlet. Procacitonin - a new marker of severe infection and sepsis[J]. Intensive Care Medicine,2000,26:S145.
2Hensel M , Volk T, Docke WD, et al. Anesthesiology, 1998,89(1):93- 104.
3Dandona P,Nix D,Wilson MF,et al. Procalcitonin increase after endotoxin injection in normal subjects [ J ]. Clin Endocrinol,1994,79:1605 - 1608.
4Whang KT,Steinwald PM,White JC,et al.Serum calcitonin precursors in sepsis and systemic inflammation[J]. Clin Endocrinol Metab, 1998,83: 3296 - 3301.
5Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med ,2002,347:465-471.
6Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J,2000,19:679-688.
7Stockley RA,O' Brien C ,Pye A,et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest,2000,117 : 1638-1645.
8van der Valk P, Monninkhof E, van der Palen J, et al. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis,2004,39:980-986.
9Pavord ID, Pizzichini MM, Pizzichini E, et al. The use of induced sputum to investigate airway inflammation. Thorax, 1997,52 : 498-501.
10Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol,1995,48:719-724.